X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
MB-106 is a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. It is being evaluated for the treatment of autoimmune diseases.
Lead Product(s): MB-106
Therapeutic Area: Immunology Product Name: MB-106
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
Under the agreement, uBriGene gains access to all of Mustang’s assets primarily relating to the manufacturing and production of cell and gene therapies, including MB-106, a first-in-class CD20-targeted autologous CAR T therapy.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: uBriGene
Deal Size: $11.0 million Upfront Cash: $6.0 million
Deal Type: Agreement July 31, 2023
Details:
MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with follicular lymphoma.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fred Hutchinson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with Waldenstrom macroglobulinemia.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fred Hutchinson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
MB-106, first-in-class CD20-targeted, autologous CAR T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“BNHL”) and chronic lymphocytic leukemia.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
The overall response for MB-106 was 96% across all dose levels and all indications. In particular, 100% complete response rates by PET scan of patients with WM (n=2) as well as of patients with B-NHL previously treated with CD19- directed CAR T cell therapy.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
The lentiviral vector drug substance used to transduce patients’ cells to create the MB-106, produced at Fred Hutch has been optimized as a third-generation CAR derived from a fully human antibody, and MB-106 is currently in a Phase 1/2 in patients with B-NHLs and CLL.
Lead Product(s): MB-106,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
MB-106 showed Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma.
Lead Product(s): MB-106,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
MB-106 (CD20-targeted autologous CAR T Cell Therapy), is a membrane-embedded surface molecule that plays a role in differentiation of B-cells into plasma cells for patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.
Lead Product(s): MB-106,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
MB-106, Company’s CD20-targeted, autologous CAR T cell therapy has been optimized as a third-generation CAR derived from a fully human antibody and is currently in a Phase 1/2 trial in patients with B-NHLs and CLL.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
This grant will contribute to Mustang’s evaluation of MB-106 in clinical trials with the hope to bring this therapeutic treatment to patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding November 01, 2021
Details:
Interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (“NHL”), have been selected for a poster presentation at the 62nd American Society of Hematology (“ASH”) Annual Meeting.
Lead Product(s): MB-106,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
The first subject treated with the optimized MB-106 manufacturing process, has achieved a complete response (CR) at the lowest starting dose in an ongoing Phase 1/2 clinical trial.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
